The primary objective of the MALAHBAR project is to evaluate the capacity of albumin PTM to predict liver disease progression over three years in chronic liver disease patients. Secondary objectives include assessing the predictive ability of different albumin isoforms and the SEB test for liver disease progression, evaluating diagnostic performances and confirming characteristic albumin isoform profiles related to specific hepatic injuries. The study could represent a significant advancement in liver disease diagnostics and management, offering new insights into the role of albumin in liver pathology. conditions: Chronic Liver Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective multicentre study of biomarker validation primaryPurpose: DIAGNOSTIC masking: NONE count: 756 type: ESTIMATED name: blood sampling measure: Ability of HSA PTM to predict the evolution of liver damage at 3 year in patients with an advanced chronic liver disease (ACLD) as recently defined in the BAVENO VII recommendations based on FibroScan. measure: ability of post-translational HSA modifications to predict the evolution of liver damage at 3 years based on liver-related events or on the worsening of the disease stage evaluated by the de Child Pugh or MELD score. measure: ability of the different isoforms of HSA to predict the evolution of liver damage at 1 and 2 years provided that data are available in the medical file. measure: ability of SEB test to predict the evolution of liver damage at 3 years (and at 1 and 2 years provided data are available in the medical file). measure: diagnostic performances of the SEB test and of the different isoforms of HSA at each stage of the liver disease. measure: confirm that the isoforms of HAS present in the characteristic patterns (type of isoform and intensity) of the nature of the liver damage. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Angers Univeristy Hospital city: Angers zip: 49100 country: France name: Jerome BOURSIER, MD role: CONTACT email: JeBoursier@chu-angers.fr name: Jerome BOURSIER, MD role: PRINCIPAL_INVESTIGATOR lat: 47.46667 lon: -0.55 facility: Limoges University Hospital city: Limoges zip: 87042 country: France name: Souleiman EL BALKHI, MD role: CONTACT email: Souleiman.ElBalkhi@chu-limoges.fr name: Paul CARRIER, MD role: CONTACT email: Paul.Carrier@chu-limoges.fr name: Paul CARRIER, MD role: PRINCIPAL_INVESTIGATOR lat: 45.83153 lon: 1.25781 facility: Poitiers University Hospital city: Poitiers zip: 86000 country: France name: Valentin ROLLE, MD role: CONTACT email: v.rolle@chu-poitiers.fr name: Valentin ROLLE, MD role: PRINCIPAL_INVESTIGATOR lat: 46.58333 lon: 0.33333 facility: Rennes University Hospital city: Rennes zip: 35000 country: France name: Florent ARTRU, MD role: CONTACT email: florent.artru@chu-rennes.fr name: Florent ARTRU, MD role: PRINCIPAL_INVESTIGATOR lat: 48.11198 lon: -1.67429 facility: Tours University Hospital city: Tours zip: 37170 country: France name: Laure ELKRIEF, MD role: CONTACT email: l.elkrief@chu-tours.fr name: Laure ELKRIEF, MD role: PRINCIPAL_INVESTIGATOR lat: 47.38333 lon: 0.68333 facility: Pointe à Pitre University Hospital city: Pointe-a-Pitre zip: 97159 country: Guadeloupe name: Moana GELU-SIMEON role: CONTACT email: moana.simeon@chu-guadeloupe.fr name: Moana GELU-SIMEON, MD role: PRINCIPAL_INVESTIGATOR lat: 16.24125 lon: -61.53614 hasResults: False